Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Reiss

Showing results (131-140 of 207) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|June 27, 2001
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapineB Conway, M A Wainberg, D Hall, et al.
AIDS (London, England)|April 1, 1995
Diarrhoea in HIV-infected patients: no evidence of cytokine-mediated inflammation in jejunal mucosaF Snijders, S J van Deventer, J F Bartelsman, et al.
The New England Journal of Medicine|May 10, 1990
Failure of zidovudine prophylaxis after accidental exposure to HIV-1J M Lange, C A Boucher, C E Hollak, et al.
Lancet (London, England)|April 28, 1999
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study GroupG J Weverling, A Mocroft, B Ledergerber, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteersR E Aarnoutse, J A H Droste, J J G van Oosterhout, et al.
HIV Clinical Trials|July 28, 2009
Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavirM G A van Vonderen, L Gras, F Wit, et al.
HIV Medicine|May 26, 2010
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudyD A Cooper, D V Cordery, P Reiss, et al.
HIV Medicine|December 2, 2017
Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfectE J Smolders, C Smit, Ctmm de Kanter, et al.
Annals of Surgical Oncology|September 25, 2001
Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV)H Wanebo, P Chougule, N Ready, et al.
The New England Journal of Medicine|February 24, 2001
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study GroupsB Ledergerber, A Mocroft, P Reiss, et al.
Pageof 21

Showing results (131-140 of 207) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|June 27, 2001
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapineB Conway, M A Wainberg, D Hall, et al.
AIDS (London, England)|April 1, 1995
Diarrhoea in HIV-infected patients: no evidence of cytokine-mediated inflammation in jejunal mucosaF Snijders, S J van Deventer, J F Bartelsman, et al.
The New England Journal of Medicine|May 10, 1990
Failure of zidovudine prophylaxis after accidental exposure to HIV-1J M Lange, C A Boucher, C E Hollak, et al.
Lancet (London, England)|April 28, 1999
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study GroupG J Weverling, A Mocroft, B Ledergerber, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteersR E Aarnoutse, J A H Droste, J J G van Oosterhout, et al.
HIV Clinical Trials|July 28, 2009
Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavirM G A van Vonderen, L Gras, F Wit, et al.
HIV Medicine|May 26, 2010
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudyD A Cooper, D V Cordery, P Reiss, et al.
HIV Medicine|December 2, 2017
Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfectE J Smolders, C Smit, Ctmm de Kanter, et al.
Annals of Surgical Oncology|September 25, 2001
Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV)H Wanebo, P Chougule, N Ready, et al.
The New England Journal of Medicine|February 24, 2001
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study GroupsB Ledergerber, A Mocroft, P Reiss, et al.
Pageof 21